Scientists conducted a laboratory study to understand how a specific type of immune cell, called a neutrophil, reacts to birch pollen allergens. They looked at what happens when the allergen is bound to a specific antibody, forming a complex. The study used neutrophils taken from people with and without birch pollen allergies in a controlled lab setting.
The researchers found that neutrophils took up these allergen-antibody complexes effectively. When the complexes were modified to reduce certain immune triggers, the neutrophils showed an enhanced ability to present the allergen to other immune cells called T-cells. However, the standard complexes also triggered a different immune response involving the release of DNA webs, which might interfere with T-cell activation.
It is important to know this was a lab study using isolated human cells, not a clinical trial in people. The results with the standard complexes on T-cell activity were inconclusive. The findings help explain a possible biological mechanism but do not show if this happens in the human body or affects allergy symptoms. More research is needed to understand if these processes are relevant for treating allergies.